Sanofi ends cancer drug trials
The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.哈希牛牛源码（www.hx198.vip）采用波场区块链高度哈希值作为统计数据，游戏数据开源、公平、无任何作弊可能性，哈希牛牛源码开放单双哈希、幸运哈希、哈希定位胆、哈希牛牛等游戏源码下载、出售。
PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.
The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.
The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.
The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.,
,ERC换TRC，TRC换ERC（www.u2u.it）是最高效的ERC换TRC，TRC换ERC的平台.ERC20 USDT换TRC20 USDT，TRC20 USDT换ERC20 USDT链上匿名完成，手续费低。
Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.
Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.
UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg